The mammalian gammaretroviruses gibbon ape leukemia virus (GALV) and feline leukemia virus subgroup B (FeLV-B) can use the same receptor, Pit1, to infect human cells. A highly polymorphic nine-residue sequence within Pit1, designated region A, has been proposed as the virus binding site, because mutations in this region abolish Pit1-mediated cellular infection by GALV and FeLV-B. However, a direct correlation between region A mutations deleterious for infection and loss of virus binding has not been established. We report that cells expressing a Pit1 protein harboring mutations in region A that abolish receptor function retain the ability to bind virus, indicating that Pit1 region A is not the virus binding site. Furthermore, we have now identified a second region in Pit1, comprising residues 232 to 260 ( Pit1 is the human ortholog of a ubiquitous multiple-membrane-spanning protein that functions as the type III sodium phosphate cotransporter (14, 19) and as the receptor for feline leukemia virus type B (FeLV-B) (33), woolly monkey virus (33), gibbon ape leukemia virus (GALV) (18), and 10A1 murine leukemia virus (10A1 MLV) (17, 38). Pit2, another type III sodium phosphate cotransporter, is the human ortholog of a highly related protein (approximately 60% amino acid identity), which functions as a receptor for amphotropic murine leukemia virus (17, 34), 10A1 MLV, and FeLV-B molecular recombinants (30), but not for GALV or naturally occurring FeLV-B isolates (21). The ability of Pit1 and Pit2 to function as discrete viral receptors with unique properties presumably is reflected in critical residue differences between these two proteins. Early efforts to identify regions within Pit1 important for virus receptor function implicated residues 550 to 558 for both GALV and FeLV-B entry. It has been proposed that this nine-Pit1-residue stretch, designated region A, is the binding site for both of these viruses (6, 11, 35) based on the following observations: (i) mutations in Pit1 region A render Pit1 nonfunctional for GALV or FeLV-B entry (3, 9, 22, 27, 31, 32); (ii) Pit2, MusPit1 (the murine ortholog of Pit1), and Pho-4 (a distantly related Neurospora crassa phosphate transporter), which are not GALV or FeLV-B receptors, become functional receptors when region A residues are substituted for the corresponding residues of these proteins (12, 13, 33); and (iii) region A is predicted by Kyte-Doolittle hydropathy plots to reside in an extracellular domain (12). It should be noted, however, that all published reports supporting the role of region A as a binding site have been based on functional assays of viral entry rather than actual receptor-binding studies (reviewed in reference 20). Therefore we sought to determine if mutations in region A that abolish virus receptor function do so by abolishing virus binding.We have used data derived from the analyses of epitopetagged Pit proteins, glycosylation studies, and transmembrane (TM) structure predictions performed by using the PHD PredictProtein algorithm (23, 24) to derive a...